It is possible that DMBT1 deletion have a more specific function in development of ALL cases without a high risk chromosomal abnormality (which are mostly classified as standard risk), since only 14% of CT+ cases have high risk biomarker (BCR-ABL1 or MLL-AF4). The gene discussed is BCR; the disease is acute lymphoblastic leukemia.